ClinicalTrials.gg
CompletedNCT01219179Updated Feb 27, 2013

Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants

An interventional study of Sterile water feedings in Extremely Low Birth Weight Infants and Hypernatremia, sponsored by Case Western Reserve University. Completed at 1 site in United States. Open to participants aged 24 Hours to 28 Weeks. Per ClinicalTrials.gov, last updated 2013-02-27.

Sponsored by Case Western Reserve University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
24 Hours to 28 Weeks
Sex
All
01

Study summary

The improved survival rate of extremely low birth weight(ELBW)infants has resulted in new fluid and electrolyte problems that have not been encountered previously,in particular electrolyte imbalance. ELBW infants are especially vulnerable to hypernatremia(serum sodium value >150 mEq/L). Hypernatremia may be due to rapid dehydration or excessive administration of intravenous fluids(IV)that contain sodium. The current treatment modality for hypernatremia is to increase IV fluids above daily requirements.Enteral sterile water feeds(ESWF)are theorized as an endogenous source of fluids that may decrease elevated electrolytes such as sodium and potassium in premature infants. By giving ESWF to decrease elevated electrolytes, there would be less need for large volumes of IVF that contribute to the co-morbidities of prematurity: bronchopulmonary dysplasia (BPD),intraventricular hemorrhage(IVH)and patent ductus arteriosus(PDA).

The purpose of this proposed study is to determine whether enteral sterile water feedings is effective in decreasing the incidence, duration and severity of hypernatremia in ELBW infants.

02

Conditions studied

  • Extremely Low Birth Weight Infants
  • Hypernatremia

Browse trials for

Keywords

  • Extremely Low Birth Weight Infants
  • Hypernatremia
  • Enteral Sterile Water Feeds
03

In context

Hypernatremia

49 studies on the registry are indexed under Hypernatremia; 8 are open to participants now.

This study's enrollment of 19 is below the median of 64 across 32 interventional studies indexed under Hypernatremia.

Browse Hypernatremia studies →

Lead sponsor

Case Western Reserve University is the lead sponsor of 160 studies on the registry; 28 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Hours to 28 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants less than or equal to 1,100 grams birth weight
  • Less than or equal to 28 weeks gestational age

Exclusion criteria

Exclusion Criteria:

  • * Congenital heart disease, other than a PDA

    • Major congenital anomalies
    • A surgical condition (gastroschisis,omphalocele)
    • Renal disease
    • Hypotension treated with pressor support
    • Reverse end diastolic flow on Doppler study prior to delivery
    • Emergency medication received in the delivery room,except fluid boluses
    • Apgar scores recorded at 10 minutes of life \< or up to 5 and/or pH less than 7.0 on the first blood gas upon admission to the NICU
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    sterile water

    Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter

    Other: Sterile water feedings

Interventions

  • OtherSterile water feedings

    Control group- no intervention Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L. The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.

06

What researchers measure

Primary outcomes

  1. serum sodium values

    electrolytes will be measured every 12 hours from admission through the first seven days of life

    Time frame: Every 12 hours for 7 days

07

Study locations

1 site
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2010
First posted
Oct 13, 2010
Start
Nov 2010
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Feb 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01219179
Responsible party
Amy Bieda (Student, Case Western Reserve University) — Principal investigator
First posted
Oct 13, 2010
Start date
Nov 2010
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Feb 27, 2013

Study contacts

Donna Dowling, PhD
study chair · Case Western Reserve University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion